| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
BT4: COST-EFFECTIVENESS OF HIGH VERSUS LOW DOSE ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEIs) IN THE TREATMENT OF CHRONIC HEART FAILURE (CHF): AN ECONOMIC ANALYSIS OF THE US ASSESSMENT OF TREATMENT WITH LISINOPRIL AND SURVIVAL (ATLAS) TRIAL
|
Schwartz, JS
|
|
2000
|
3 |
2 |
p. 65-
1 p.
|
artikel
|
| 2 |
BT2: DIRECT COSTS OF OBESITY IN PORTUGAL
|
Pereira, J
|
|
2000
|
3 |
2 |
p. 64-65
2 p.
|
artikel
|
| 3 |
BT1: POSTOPERATIVE PAIN SEVERITY AFTER ABDOMINAL OR ORTHOPEDIC SURGERY: INTERIM RESULTS
|
Strassels, S
|
|
2000
|
3 |
2 |
p. 64-
1 p.
|
artikel
|
| 4 |
BT3: THE COMPARATIVE ECONOMIC VALUE OF RALTITREXED AND 5-FU PLUS LEUCOVORIN
|
Simons, WR
|
|
2000
|
3 |
2 |
p. 65-
1 p.
|
artikel
|
| 5 |
CAN3: BASELINE COST OF ILLNESS OF PARKINSON'S DISEASE IN A LARGE HEALTHCARE PLAN
|
Heaton, AH
|
|
2000
|
3 |
2 |
p. 57-
1 p.
|
artikel
|
| 6 |
CAN1: COMPARISON OF COSTS OF ASTHMA TREATMENT BETWEEN PATIENTS TREATED WITH ANTI-INFLAMMATORIES VERSUS BRONCHODILATORS
|
Huse, DM
|
|
2000
|
3 |
2 |
p. 56-57
2 p.
|
artikel
|
| 7 |
CAN4: IS PRIOR COMMUNITY ANTIBIOTIC TREATMENT OF PATIENTS HOSPITALISED WITH LOWER RESPIRATORY TRACT INFECTION ASSOCIATED WITH REDUCED IN-HOSPITAL MORTALITY AND LENGTH OF STAY?
|
Steinke, D
|
|
2000
|
3 |
2 |
p. 58-
1 p.
|
artikel
|
| 8 |
CAN2: SHORTER HOSPITAL LENGTH OF STAY FOR CORONARY ANGIOPLASTY PATIENTS WHO RECEIVE ABCIXIMAB VERSUS EPTIFIBATIDE ORTIROFIBAN
|
Lage, MJ
|
|
2000
|
3 |
2 |
p. 57-
1 p.
|
artikel
|
| 9 |
CEB8: A DECISION ANALYTIC MODEL MEASURING THE COST-EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN HIV+ PATIENTS WITH HIGH VERSUS LOW BASELINE VIRAL LOAD: AN INDINAVIR PLUS LAMIVUDINE ANDZIDOVUDINE EXAMPLE
|
Risebrough, NA
|
|
2000
|
3 |
2 |
p. 67-
1 p.
|
artikel
|
| 10 |
CEB2: COST-EFFECTIVENESS OF MENINGOCOCCAL VACCINE IN THE UK
|
Brown, RE
|
|
2000
|
3 |
2 |
p. 58-59
2 p.
|
artikel
|
| 11 |
CEB3: COST-EFFECTIVENESS OF PREVENTION OF CORONARY HEART DISEASE (CHD) WITH SIMVASTATIN IN POLAND
|
Kuzniar, J
|
|
2000
|
3 |
2 |
p. 59-
1 p.
|
artikel
|
| 12 |
CEB5: MEASURING PATIENT PREFERENCES USING CONJOINT ANALYSIS: A NEW APPROACH
|
Phillips, KA
|
|
2000
|
3 |
2 |
p. 66-
1 p.
|
artikel
|
| 13 |
CEB1: PHARMACOGENOMICS: EVALUATING THE ECONOMIC IMPACT
|
Veenstra, DL
|
|
2000
|
3 |
2 |
p. 58-
1 p.
|
artikel
|
| 14 |
CEB7: SOCIOECONOMIC EFFICIENCY OF THE ADJUVANT TREATMENT WITH ACAMPROSATE IN MAINTAINING ABSTINENCE IN ALCOHOL DEPENDENT PATIENTS
|
Kilburg, A
|
|
2000
|
3 |
2 |
p. 66-67
2 p.
|
artikel
|
| 15 |
CEB4: THE COST-EFFECTIVENESS OF FIXED-DOSE COMBINATION OF DICLOFENAC AND MISOPROSTOL IN PREVENTION OF NSAID-INDUCED ULCERS IN RHEUMATOID ARTHRITIS PATIENTS IN POLAND
|
Orlewska, E
|
|
2000
|
3 |
2 |
p. 59-
1 p.
|
artikel
|
| 16 |
CEB6: THE IMPORTANCE OF COMPARABLE PATIENT POPULATIONS IN COST-EFFECTIVENESS ANALYSES: TOLTERODINE VERSUS OXYBUTININ XL FOR TREATING OVERACTIVE BLADDER
|
Schonfeld, WH
|
|
2000
|
3 |
2 |
p. 66-
1 p.
|
artikel
|
| 17 |
D3: A PHARMACOECONOMIC MODEL TO ASSESS THE COST-EFFECTIVENESS OF TROVAFLOXACIN COMPARED TO CEFTAZIDIME FOR NOSOCOMIAL PNEUMONIA IN A PUBLIC HOSPITAL SETTING IN HONG KONG
|
Lee, KKC
|
|
2000
|
3 |
2 |
p. 49-50
2 p.
|
artikel
|
| 18 |
D2: COST UTILITY OF DOCETAXEL VS VINORELBINE OR PACLITAXEL IN ADVANCED BREAST CANCER
|
Brown, R
|
|
2000
|
3 |
2 |
p. 49-
1 p.
|
artikel
|
| 19 |
D1: DEVELOPMENT AND VALIDATION OF A SCREENING INSTRUMENT FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD)
|
Fullerton, S
|
|
2000
|
3 |
2 |
p. 49-
1 p.
|
artikel
|
| 20 |
D4: ECONOMIC ANALYSIS OF WARFARIN IN OUTPATIENTS WITH ATRIAL FIBRILLATION: INNOVATOR VERSUS GENERIC
|
Mittmann, N
|
|
2000
|
3 |
2 |
p. 50-
1 p.
|
artikel
|
| 21 |
DH1: AN ANALYSIS OF THE IMPACT OF MEDICATION NON-ADHERENCE AND TYPE OF MEDICATION ON OUTCOME DOMAINS USING THE SCAP HEALTH QUESTIONNAIRE
|
Russo, P
|
|
2000
|
3 |
2 |
p. 52-
1 p.
|
artikel
|
| 22 |
DH2: MEDICARE'S EXTENDED IMMUNOSUPPRESSION COVERAGE IMPROVED MIDDLE-INCOME RENAL GRAFT SURVIVAL
|
Woodward, RS
|
|
2000
|
3 |
2 |
p. 52-53
2 p.
|
artikel
|
| 23 |
DH3: PUBLIC REPORT SPURS HOSPITAL MORTALITY REDUCTION
|
Czerwinski, AA
|
|
2000
|
3 |
2 |
p. 53-
1 p.
|
artikel
|
| 24 |
DH4: SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP): IMPACT OF CLINICAL AND FUNCTIONAL STATUS AND TYPE OF MEDICATION TREATMENT ON OUTPATIENT PSYCHIATRIC UTILIZATION
|
Russo, P
|
|
2000
|
3 |
2 |
p. 53-
1 p.
|
artikel
|
| 25 |
DUC1: DRUG UTILIZATION OF CISAPRIDE AND CONTRAINDICATED DRUGS IN A US MANAGED CARE POPULATION
|
Guo, JJ
|
|
2000
|
3 |
2 |
p. 59-60
2 p.
|
artikel
|
| 26 |
DUC4: HIGH USERS OF β2-AGONISTS: ARE MEDICAID RECIPIENTS BEING TREATED ACCORDING TO NATIONAL ASTHMA GUIDELINES?
|
Reddy, P
|
|
2000
|
3 |
2 |
p. 61-
1 p.
|
artikel
|
| 27 |
DUC2: INSURANCE CLAIMS COSTS FOR OVERACTIVE BLADDER IN ADULTS
|
Zhou, Z
|
|
2000
|
3 |
2 |
p. 60-
1 p.
|
artikel
|
| 28 |
DUC3: SMOKING CESSATION SUCCESS RATES WITH DRUG THERAPY IN A SAMPLE OF MEDICAID PATIENTS
|
Fincham, JE
|
|
2000
|
3 |
2 |
p. 60-
1 p.
|
artikel
|
| 29 |
ICP3: FACTORS INFLUENCING PATIENT WILLINGNESS TO PAY FOR DIABETES DISEASE STATE MANAGEMENT PROGRAMS
|
Barrier, JC
|
|
2000
|
3 |
2 |
p. 56-
1 p.
|
artikel
|
| 30 |
ICP4: HEALTH STATE PREFERENCES IN DIABETIC PERIPHERAL NEUROPATHY
|
Devine, EB
|
|
2000
|
3 |
2 |
p. 56-
1 p.
|
artikel
|
| 31 |
ICP1: INCORPORATING MEASUREMENT OF INDIRECT COSTS IN THE EVALUATION OF AN ASTHMA HEALTH MANAGEMENT PROGRAM
|
Ershoff, DH
|
|
2000
|
3 |
2 |
p. 55-
1 p.
|
artikel
|
| 32 |
ICP2: THE RELATIVE EFFECTIVENESS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) AND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN REDUCING WORKER ABSENTEEISM
|
Treglia, M
|
|
2000
|
3 |
2 |
p. 55-56
2 p.
|
artikel
|
| 33 |
MI4: A FRAMEWORK FOR COST-EFFECTIVENESS ANALYSIS FROM CLINICAL TRIAL DATA
|
O'Hagan, A
|
|
2000
|
3 |
2 |
p. 62-
1 p.
|
artikel
|
| 34 |
MI1: IDENTIFYING FACTORS ASSOCIATED WITH HIGH AND LOW COST ASTHMATICS: OPPORTUNITIES FOR DISEASE MANAGEMENT USING AUTOMATIC INTERACTION DETECTION
|
Boscarino, JA
|
|
2000
|
3 |
2 |
p. 61-
1 p.
|
artikel
|
| 35 |
MI3: RELIABILITY AND VALIDITY OF INTERNATIONAL PROSTATE SYMPTOM SCORE (l-PSS) FOR EARLY ASSESSMENT OF SYMPTOMS IN THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA (BPH)
|
Singh, A
|
|
2000
|
3 |
2 |
p. 62-
1 p.
|
artikel
|
| 36 |
Ml2: THE NUMBER NEEDED TO TREAT APPROACH: EVALUATING THE CLINICAL RELEVANCE OF FEXOFENADINE IN SEASONAL ALLERGIC RHINITIS
|
Crawford, B
|
|
2000
|
3 |
2 |
p. 61-62
2 p.
|
artikel
|
| 37 |
PAR5: COMPARING THE HEALTH RELATED QUALITY OF LIFE OUTCOMES OF TREATMENT FOR EARLY RHEUMATOID ARTHRITIS
|
Bury-Maynard, D
|
|
2000
|
3 |
2 |
p. 97-
1 p.
|
artikel
|
| 38 |
PAR4: NSAID UTILIZATION AMONG COMMERCIALLY INSURED MEMBERS IN A MANAGED CARE ENVIRONMENT
|
Hall, J
|
|
2000
|
3 |
2 |
p. 97-
1 p.
|
artikel
|
| 39 |
PAR2: PHARMACOECONOMICAL ANALYSIS OF NON-STEROID ANTI-INFLAMMATORY DRUGS IN RHEUMATOLOGY
|
Nasonova, VA
|
|
2000
|
3 |
2 |
p. 96-
1 p.
|
artikel
|
| 40 |
PAR6: QUALITY OF LIFE MEASUREMENTS AS PREDICTORS OF CHANGE IN THERAPY IN PATIENTS WITH MUSCULOSKELETAL DISORDERS
|
Yazdani, C
|
|
2000
|
3 |
2 |
p. 97-98
2 p.
|
artikel
|
| 41 |
PAR3: REDUCED UTILIZATION OF ANTIULCERANT DRUGS WITH CELECOXIB: FINDINGS OF THE PAINLESS TRIAL
|
Castaldo, RS
|
|
2000
|
3 |
2 |
p. 96-
1 p.
|
artikel
|
| 42 |
PAR1: THE BURDEN OF EARLY RHEUMATOID ARTHRITIS ON HEALTH RELATED QUALITY OF LIFE
|
Kosinski, M
|
|
2000
|
3 |
2 |
p. 95-96
2 p.
|
artikel
|
| 43 |
PAR7: THE LONGTERM SAFETY AND EFFECTIVENESS OF CYCLOSPORINE IN PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS (RA)
|
Marra, CA
|
|
2000
|
3 |
2 |
p. 98-
1 p.
|
artikel
|
| 44 |
PCD26: A CLOSER LOOK AT HYPERTENSION PRACTICE PATTERNS AND MEDICATION COMPLIANCE
|
Guico-Pabia, CJ
|
|
2000
|
3 |
2 |
p. 76-77
2 p.
|
artikel
|
| 45 |
PCD8: A MODEL COMPARING NITROGLYCERIN FORMULATIONS FOR ACUTE ANGINA EPISODES: ASSESSING THE ECONOMIC ISSUES
|
Bell, CF
|
|
2000
|
3 |
2 |
p. 70-
1 p.
|
artikel
|
| 46 |
PCD2: ASSESSING THE BURDEN OF ILLNESS IN ELDERLY VERSUS YOUNGER ACUTE CORONARY SYNDROME PATIENTS
|
Eisenstein, EL
|
|
2000
|
3 |
2 |
p. 68-
1 p.
|
artikel
|
| 47 |
PCD24: CONJOINT ANALYSIS COMPARING PREFERENCES FOR TREATMENT OUTCOMES IN HEART FAILURE AND HEALTHY PATIENTS: LONGEVITY VERSUS SYMPTOM RELIEF
|
Oates, MB
|
|
2000
|
3 |
2 |
p. 76-
1 p.
|
artikel
|
| 48 |
PCD6: COST ANALYSIS OF ANTIHYPERTENSIVE DRUG USE IN TURKEY
|
Sapci, H
|
|
2000
|
3 |
2 |
p. 69-
1 p.
|
artikel
|
| 49 |
PCD13: COST-EFFECTIVENESS ANALYSIS OF ENALAPRIL IN THE MANAGEMENT OF CHF IN POLAND
|
Orlewska, E
|
|
2000
|
3 |
2 |
p. 71-72
2 p.
|
artikel
|
| 50 |
PCD9: COST-EFFECTIVENESS OF RAMIPRIL IN HYPERTENSIVE PATIENTS WITH NEPHROPATHY IN GERMANY
|
Schadlich, PK
|
|
2000
|
3 |
2 |
p. 70-
1 p.
|
artikel
|
| 51 |
PCD16: COST-EFFECTIVENESS OF TIROFIBAN PLUS HEPARIN AS COMPARED WITH HEPARIN ONLY IN TREATING UNSTABLE ANGINA
|
Shi, L
|
|
2000
|
3 |
2 |
p. 73-
1 p.
|
artikel
|
| 52 |
PCD5: COSTS OF LEFT VENTRICULAR ASSIST DEVICE VERSUS POSITIVE INOTROPIC THERAPY AS A BRIDGE TO HEART TRANSPLANT
|
Stanek, EJ
|
|
2000
|
3 |
2 |
p. 69-
1 p.
|
artikel
|
| 53 |
PCD20: ESTIMATING THE EFFECTS OF POLYPHARMACY ON HOSPITALIZATION IN AN ELDERLY CHF MEDICAID POPULATION
|
Bramley, T
|
|
2000
|
3 |
2 |
p. 74-
1 p.
|
artikel
|
| 54 |
PCD15: HOW MEANINGFUL ARE THE CORONARY BENEFITS OF SELECTIVE ESTROGEN RECEPTOR MODULATORS?
|
Russell, MW
|
|
2000
|
3 |
2 |
p. 72-
1 p.
|
artikel
|
| 55 |
PCD10: IMPACT OF NEW STATIN DOSES ON MARKET SEGMENTATION
|
Miller, JD
|
|
2000
|
3 |
2 |
p. 70-71
2 p.
|
artikel
|
| 56 |
PCD3: INCIDENCE, UTILIZATION OF HEALTH CARE AND COSTS OF STROKE
|
Wilson, L
|
|
2000
|
3 |
2 |
p. 68-
1 p.
|
artikel
|
| 57 |
PCD1: INCORPORATING BOTH DIASTOLIC AND SYSTOLIC PRESSURES IN A MODEL OF THE BENEFITS OF ACHIEVING HYPERTENSION TREATMENT TARGETS
|
Huse, DM
|
|
2000
|
3 |
2 |
p. 67-68
2 p.
|
artikel
|
| 58 |
PCDI7: THE EFFECTS OF PAYOR STATUS ON PROCEDURE USE AND OUTCOMES OF PATIENTS WITH CONGESTIVE HEART FAILURE
|
Kroch, E
|
|
2000
|
3 |
2 |
p. 73-
1 p.
|
artikel
|
| 59 |
PCD3: PROSPECTIVE EVALUATION OF AN INFORMATION DISSEMINATION PROGRAM INCORPORATING PEER COMPARISON FEEDBACK IN PEPTIC ULCER DISEASE MANAGEMENT
|
Dennett, SL
|
|
2000
|
3 |
2 |
p. 152-153
2 p.
|
artikel
|
| 60 |
PCD19: RELATIONSHIP BETWEEN DAILY DOSE FREQUENCY AND ADHERENCE TO ANTIHYPERTENSIVE PHARMACOTHERAPY: UPDATE OF A META-ANALYSIS
|
Iskedjian, M
|
|
2000
|
3 |
2 |
p. 74-
1 p.
|
artikel
|
| 61 |
PCD7: SOCIECONOMIC EVALUATION OF CILOSTAZOL FOR THE SECONDARY PREVENTION OF CEREBRAL INFARCTION IN JAPAN
|
Kobayashi, M
|
|
2000
|
3 |
2 |
p. 69-70
2 p.
|
artikel
|
| 62 |
PCD12: SPIRONOLACTONE IN HEART FAILURE: LIFE AND COST SAVING TREATMENT IN POLAND
|
Kuzniar, J
|
|
2000
|
3 |
2 |
p. 71-
1 p.
|
artikel
|
| 63 |
PCD25: SYSTEMATIC REVIEW EVIDENCE ON TREATING HYPERTENSION IN OLDER ADULTS
|
McDonagh, M
|
|
2000
|
3 |
2 |
p. 76-
1 p.
|
artikel
|
| 64 |
PCD11: THE COST-EFFECTIVENESS ANALYSIS AS A SUBSTANTIATION OF DIAGNOSTIC AND TREATMENT OF EARLY STAGE OF HEART FAILURE
|
Gorokhova, SG
|
|
2000
|
3 |
2 |
p. 71-
1 p.
|
artikel
|
| 65 |
PCD22: THE EFFECT OF NATIONALITY ON HEALTH-RELATED QUALITY OF LIFE IN THE GUSTO-I ANGIOGRAPHIC TRIAL
|
Coyne, K
|
|
2000
|
3 |
2 |
p. 75-
1 p.
|
artikel
|
| 66 |
PCD4: THE IMPACT OF SECONDARY EVENTS ON THE COST OF ACUTE MYOCARDIAL INFARCTION
|
O'Brien, J
|
|
2000
|
3 |
2 |
p. 68-69
2 p.
|
artikel
|
| 67 |
PCD18: THE PERCEPTUAL EFFECTIVENESS INDEX: A NEW APPROACH FOR EVALUATING OUTCOMES OF ANTI-HYPERTENSIVE THERAPY
|
Leidy, NK
|
|
2000
|
3 |
2 |
p. 73-74
2 p.
|
artikel
|
| 68 |
PCD14: TREATMENT COST OF SIDE EFFECTS OF ANTIARRHYTHMIC DRUGS IN THE USA
|
Bhattacharyya, SK
|
|
2000
|
3 |
2 |
p. 72-
1 p.
|
artikel
|
| 69 |
PCD21: TWO-YEAR MEDICATION COMPLIANCE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
|
Plante, M
|
|
2000
|
3 |
2 |
p. 74-75
2 p.
|
artikel
|
| 70 |
PCD23: UNADJUSTED INPATIENT COSTS AND MORTALITY FOR FOUR CEREBROVASCULAR EVENTS FOR PATIENTS TREATED AT COMMUNITY TEACHING AND NONTEACHING HOSPITALS
|
Reed, SD
|
|
2000
|
3 |
2 |
p. 75-
1 p.
|
artikel
|
| 71 |
PCH4: APPLICATION OF PHARMACOECONOMICS AND OUTCOMES RESEARCH ON DECISION-MAKING PATTERNS BY MEDICAL ONCOLOGISTS
|
Sarpong, DF
|
|
2000
|
3 |
2 |
p. 129-130
2 p.
|
artikel
|
| 72 |
PCH17: CONVENIENCE IS THE MAIN REASON WHY OVARIAN CANCER PATIENTS PREFER ORAL REGIMEN
|
Calhoun, EA
|
|
2000
|
3 |
2 |
p. 134-135
2 p.
|
artikel
|
| 73 |
PCH5: COST-EFFECTIVENESS OF EARLY DETECTION AND PREVENTION OF COLORECTAL CANCER BY SCREENING WITH FECAL OCCULT BLOOD TESTS
|
Parson, RE
|
|
2000
|
3 |
2 |
p. 130-
1 p.
|
artikel
|
| 74 |
PCH7: COST-EFFECTIVENESS OF RITUXIMAB IN RELAPSED, REFRACTORY, LOW-GRADE NON-HODGKIN'S LYMPHOMA
|
Cattaneo, MJ
|
|
2000
|
3 |
2 |
p. 130-131
2 p.
|
artikel
|
| 75 |
PCH15: COST-EFFECTIVENESS OF TAMOXIFEN IN BREAST CANCER RISK REDUCTION
|
Sengupta, N
|
|
2000
|
3 |
2 |
p. 134-
1 p.
|
artikel
|
| 76 |
PCH14: EFFECTIVENESS OF ERYTHROPOIETIN IN CANCER PATIENTS
|
Morris, C
|
|
2000
|
3 |
2 |
p. 133-
1 p.
|
artikel
|
| 77 |
PCH9: PATTERNS OF EPOETIN ALPHA UTILIZATION IN ANEMIC CANCER PATIENTS
|
Scott, WG
|
|
2000
|
3 |
2 |
p. 131-132
2 p.
|
artikel
|
| 78 |
PCH8: PHARMACOECONOMICS OF COMBINATION OF CHEMOTHERAPY WITH DOCETAXEL IN ADVANCED BREAST CANCER
|
Poddubnaya, IV
|
|
2000
|
3 |
2 |
p. 131-
1 p.
|
artikel
|
| 79 |
PCH12: RACIAL DIFFERENCES IN THE COST OF TREATING EARLY STAGE PROSTATE CANCER
|
Brandeis, J
|
|
2000
|
3 |
2 |
p. 132-133
2 p.
|
artikel
|
| 80 |
PCH11: SYMPTOMATIC ANEMIA DURING CANCER CHEMOTHERAPY: rhERYTHROPOIETIN (rhEPO) AND QUALITY OF LIFE
|
Bonicatto, S
|
|
2000
|
3 |
2 |
p. 132-
1 p.
|
artikel
|
| 81 |
PCN13: COLONOSCOPY CHARGES IN A MANAGED CARE POPULATION: DIFFERENCES BASED ON POLYPECTOMY AND MALIGNANCY STATUS
|
Gandhi, SK
|
|
2000
|
3 |
2 |
p. 133-
1 p.
|
artikel
|
| 82 |
PCN6: COST-EFFECTIVENESS OF GENETIC TESTING IN HEREDITARY NON-POLYPOSIS COLORECTAL CANCER
|
Henderson, LB
|
|
2000
|
3 |
2 |
p. 130-
1 p.
|
artikel
|
| 83 |
PCN1O: PSYCHOMETRIC VALIDITY OF QUALITY OF LIFE AND UTILITY MEASURES IN NON-SMALL CELL LUNG CANCER (NSCLC): A LITERATURE REVIEW
|
Emery, MP
|
|
2000
|
3 |
2 |
p. 132-
1 p.
|
artikel
|
| 84 |
PCN1: OUTCOMES AND COSTS OF ACUTE MYELOID LEUKEMIA OVER ONE YEAR FOLLOWING DIAGNOSIS: AN ANALYSIS OF SEER-MEDICARE DATA
|
Menzin, J
|
|
2000
|
3 |
2 |
p. 128-
1 p.
|
artikel
|
| 85 |
PCN3: PREDICTORS OF CERVICAL CANCER INPATIENT ADMISSION COSTS BY STAGE
|
Berg, GD
|
|
2000
|
3 |
2 |
p. 129-
1 p.
|
artikel
|
| 86 |
PCN16: VALIDITY OF THE TIME-TRADE OFF TECHNIQUE IN DETERMINING PREFERENCES FOR THE TREATMENT OF PROSTATE CANCER
|
Watkins Bruner, D
|
|
2000
|
3 |
2 |
p. 134-
1 p.
|
artikel
|
| 87 |
PDB4: COST-EFFECTIVENESS OF DIABETIC FOOT ULCER TREATMENT WITH AUTOLOGOUS PLATELET RELEASATE
|
Kantor, J
|
|
2000
|
3 |
2 |
p. 136-
1 p.
|
artikel
|
| 88 |
PDB5: COST-EFFECTIVENESS OF RENTINOPATHY SCREENING IN PEDIATRIC PATIENTS WITH TYPE I DIABETES MELLITUS
|
Li, J
|
|
2000
|
3 |
2 |
p. 136-137
2 p.
|
artikel
|
| 89 |
PDB9: COST OF CONCOMITANT ILLNESSES AMONG PATIENTS WITH HYPERTENSION AND DIABETES
|
Farquhar, IV
|
|
2000
|
3 |
2 |
p. 138-
1 p.
|
artikel
|
| 90 |
PDB10: ECONOMIC OUTCOMES OF HMG CoA REDUCTASE INHIBITORS IN A HYPERTENSIVE DIABETIC POPULATION IN A MANAGED CARE ORGANIZATION
|
White, TJ
|
|
2000
|
3 |
2 |
p. 138-139
2 p.
|
artikel
|
| 91 |
PDB11: EVALUATION OF A DIABETES DISEASE MANAGEMENT PROGRAM IN A NURSING HOME
|
Longe, RL
|
|
2000
|
3 |
2 |
p. 139-
1 p.
|
artikel
|
| 92 |
PDB6: EVALUATION OF CLINICAL AND DEMOGRAPHIC FACTORS ASSOCIATED WITH DIABETIC FOOT ULCER TREATMENT COSTS
|
Wade, SW
|
|
2000
|
3 |
2 |
p. 137-
1 p.
|
artikel
|
| 93 |
PDB8: HEALTH RELATED QUALITY OF LIFE (HRQOL) MEASURES IN TYPE 2 DIABETES
|
Chang, J
|
|
2000
|
3 |
2 |
p. 138-
1 p.
|
artikel
|
| 94 |
PDB1: RESOURCE USE AND COST ASSOCIATED WITH MICRO- AND MACROVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES
|
Goertz, A
|
|
2000
|
3 |
2 |
p. 135-
1 p.
|
artikel
|
| 95 |
PDB3: THE EFFECTS OF AGE AND COMPLICATIONS ON THE COST OF MANAGING MEMBERS WITH TYPE 2 DIABETES MELLITUS
|
Martinson, MS
|
|
2000
|
3 |
2 |
p. 136-
1 p.
|
artikel
|
| 96 |
PDB2: THE EFFECTS OF AGE AND COMPLICATIONS ON THE COST OF MANAGING MEMBERS WITH TYPE I DIABETES MELLITUS
|
Martinson, MS
|
|
2000
|
3 |
2 |
p. 135-136
2 p.
|
artikel
|
| 97 |
PDB7: TREATMENT COSTS OF TYPE-2 DIABETES MELLITUS PATIENTS WITH AND WITHOUT SELECTED CARDIOVASCULAR COMORBIDITIES
|
Bhattacharyya, SK
|
|
2000
|
3 |
2 |
p. 137-138
2 p.
|
artikel
|
| 98 |
PDH28: A DRUG COST MODEL FOR A CAPITATED PATIENT POPULATION WITHIN AN INTEGRATED HEALTH CARE SYSTEM
|
Patel, RP
|
|
2000
|
3 |
2 |
p. 164-
1 p.
|
artikel
|
| 99 |
PDH6: ADVANTAGES AND LIMITS OF THE FRENCH HOSPITAL DATABASE (PMSI) ON DESCRIPTION OF HAEMOPHILIA MANAGEMENT AND COSTS
|
Jasso-Mosqueda, JG
|
|
2000
|
3 |
2 |
p. 155-
1 p.
|
artikel
|
| 100 |
PDH19: ANALYSIS OF THE TOTAL COST AND RESOURCES CONSUMED IN CASES OF SINGLE AND CONCURRENT CHRONIC ILLNESS
|
Garis, RL
|
|
2000
|
3 |
2 |
p. 160-
1 p.
|
artikel
|
| 101 |
PDH26: A NATIONAL SURVEY OF DECISION-MAKERS IN MANAGED CARE ON THEIR VIEWS AND USE OF PHARMACOECONOMIC INFORMATION
|
Motheral, B
|
|
2000
|
3 |
2 |
p. 163-
1 p.
|
artikel
|
| 102 |
PDH25: A QUALITATIVE ASSESSMENT OF MANAGED CARE DECISION-MAKER'S VIEWS AND USE OF PHARMACOECONOMIC INFORMATION
|
Grizzle, A
|
|
2000
|
3 |
2 |
p. 162-163
2 p.
|
artikel
|
| 103 |
PDH12: A RANDOMIZED CONTROLLED MULTI-CENTER STUDY EVALUATING THE EFFECT OF PHARMACEUTICAL CARE ON CHANGES IN QUALITY OF LIFE
|
Malone, DC
|
|
2000
|
3 |
2 |
p. 157-158
2 p.
|
artikel
|
| 104 |
PDH17: ARE THE BRITISH GOVERNMENT'S HEALTHCARE REFORMS TARGETING PATIENT'S NEEDS?: EVIDENCE FROM A COMPARISON OF TWO GP SURVEYS ON MUSCULOSKELETAL CARE
|
Dickson, DJ
|
|
2000
|
3 |
2 |
p. 159-
1 p.
|
artikel
|
| 105 |
PDH14: COMPLIANCE AND PERSISTENCY BENEFITS ACHIEVED BY UTILIZING A ONCE DAILY EXTENDED RELEASE MEDICATION VS. A TWICE DAILY REGIMEN
|
Dezii, CM
|
|
2000
|
3 |
2 |
p. 158-
1 p.
|
artikel
|
| 106 |
PDH20: CONTENT ANALYSIS OF PHARMACOECONOMIC ADVERTISING IN SPECIALTY AND PRIMARY CARE JOURNALS
|
Sullivan, PW
|
|
2000
|
3 |
2 |
p. 161-
1 p.
|
artikel
|
| 107 |
PDH32: COST IMPACT OF A PRESCRIPTION BENEFIT CHANGE IN A MEDICARE MANAGED CARE PLAN
|
Balkrishnan, R
|
|
2000
|
3 |
2 |
p. 165-
1 p.
|
artikel
|
| 108 |
PDH9: DRUG AND EXAMINATION IN RELATION TO THE TOTAL THERAPY COSTS—A COST MANAGEMENT DILEMMA?
|
Schmelzer, A
|
|
2000
|
3 |
2 |
p. 156-
1 p.
|
artikel
|
| 109 |
PDH1: ECONOMIC IMPLICATIONS FOR SAFETY-NET HOSPITALS: SCREENING FOR HEPATITIS C
|
Singer, ME
|
|
2000
|
3 |
2 |
p. 153-
1 p.
|
artikel
|
| 110 |
PDH18: ENTER THE DRAGON: PHARMACOECONOMICS IN ASIA
|
Pang, F
|
|
2000
|
3 |
2 |
p. 159-160
2 p.
|
artikel
|
| 111 |
PDH33: EVALUATION AND TREATMENT OF SHORT STATURE: NATIONAL COOPERATIVE GROWTH STUDY (NCGS) EXPERIENCE
|
Blethen, SL
|
|
2000
|
3 |
2 |
p. 165-166
2 p.
|
artikel
|
| 112 |
PDH11: EVALUATION OF CIGARETTE SMOKER'S PERCEPTIONS OF SMOKING CESSATION AND THE ROLE OF HEALTH CARE PROFESSIONALS
|
Dodd, MA
|
|
2000
|
3 |
2 |
p. 157-
1 p.
|
artikel
|
| 113 |
PDH29: FACTORS AFFECTING ASTHMATIC, DIABETIC, AND HYPERTENSIVE PATIENT SELF-REPORTED COMPLIANCE IN A PHARMACEUTICAL CARE DEMONSTRATION PROJECT
|
Chaikledkaew, U
|
|
2000
|
3 |
2 |
p. 164-
1 p.
|
artikel
|
| 114 |
PDH2: FACTORS RELATED TO PRESCRIPTION DRUG EXPENDITURE GROWTH: VOLUME VS. PRICE
|
Chawla, AJ
|
|
2000
|
3 |
2 |
p. 153-154
2 p.
|
artikel
|
| 115 |
PDH5: HEALTH CARE EXPENDITURE IN AN HMO BEFORE AND AFTER AN EXCLUSIVE PHARMACY PARTNERSHIP
|
Peris, A
|
|
2000
|
3 |
2 |
p. 155-
1 p.
|
artikel
|
| 116 |
PDH31: HEALTH RELATED QUALITY OF LIFE AND REGULATORY ISSUES: COMPARISON OF US AND EUROPEAN INITIATIVES
|
Marquis, P
|
|
2000
|
3 |
2 |
p. 165-
1 p.
|
artikel
|
| 117 |
PDH16: IDENTIFYING PATIENTS WITH PSYCHOSES IN A MEDICAID MANAGED CARE ORGANIZATION WITH CARVED-OUT BEHAVIORAL HEALTH SERVICES
|
Bachleda, MJ
|
|
2000
|
3 |
2 |
p. 159-
1 p.
|
artikel
|
| 118 |
PDH22: MODELLING THE BENEFITS OF VERTEPORFIN THERAPY IN MACULAR DEGENERATION
|
Smith, D
|
|
2000
|
3 |
2 |
p. 161-162
2 p.
|
artikel
|
| 119 |
PDH1O: POTENTIAL VALUE FOR MONEY OF RESEARCH: BETA INTERFERON AND THE UK-MS STUDY
|
Davies, L
|
|
2000
|
3 |
2 |
p. 156-157
2 p.
|
artikel
|
| 120 |
PDH24: PHARMACEUTICAL INDUSTRY PERCEPTIONS OF THE USE OF PHARMACOECONOMIC DATA BY HEALTH CARE ORGANIZATIONS
|
Armstrong, EP
|
|
2000
|
3 |
2 |
p. 162-
1 p.
|
artikel
|
| 121 |
PDH3: PHARMACEUTICAL PRICE CONTROLS AND POSITIVE DRUG LIST EFFECTS ON TOTAL AND SOCIAL INSURANCE EXPENDITURES
|
Karokis, A
|
|
2000
|
3 |
2 |
p. 154-
1 p.
|
artikel
|
| 122 |
PDH21: PRE-POST AND BETWEEN GROUP DIFFERENCES IN PATIENT OUTCOMES IN A PHARMACEUTICAL CARE INTERVENTION PROJECT
|
Kamath, TV
|
|
2000
|
3 |
2 |
p. 161-
1 p.
|
artikel
|
| 123 |
PDH13: QUALITY OF CARE INFERENCES FROM MULTIVARIATE ANALYSIS OF AMBULATORY DATA
|
Kroch, E
|
|
2000
|
3 |
2 |
p. 158-
1 p.
|
artikel
|
| 124 |
PDH23: RELEVANCE OF PHARMACOECONOMICS AND HEALTH OUTCOMES INFORMATION TO HEALTH CARE DECISION-MAKERS IN THE UNITED STATES
|
Cox, E
|
|
2000
|
3 |
2 |
p. 162-
1 p.
|
artikel
|
| 125 |
PDH30: ROLE OF HRQL EVALUATION IN THE DRUG REGULATORY PROCESS: PRELIMINARY RESULTS FROM A EUROPEAN REGULATORY SURVEY
|
Acquadro, C
|
|
2000
|
3 |
2 |
p. 164-165
2 p.
|
artikel
|
| 126 |
PDH8: SUBSPECIALISTS: DO THEY PROVIDE BETTER QUALITY AND MORE EFFICIENT CARE? AN ANALYSIS OF OUTCOMES DATA FROM 6 HOSPITALS
|
Weingarten, SR
|
|
2000
|
3 |
2 |
p. 156-
1 p.
|
artikel
|
| 127 |
PDH4: TECHNOLOGY ASSESSMENT IN THE US: WHAT DO PAYERS UNDERSTAND AND WHAT INFORMATION DO THEY WANT?
|
Evans, C
|
|
2000
|
3 |
2 |
p. 154-155
2 p.
|
artikel
|
| 128 |
PDH7: THE IMPACT OF LOCUS OF CONTROL ON COMPLIANCE
|
Reed, P
|
|
2000
|
3 |
2 |
p. 155-156
2 p.
|
artikel
|
| 129 |
PDH27: THE SATISFACTION AND ECONOMIC EVALUATION OF CONVERTING A TRADITIONAL HOSPITAL SYSTEM USING A UNIT DOSE SYSTEM, AT A HOSPITAL IN BARBADOS, WEST INDIES
|
Griffith, JA
|
|
2000
|
3 |
2 |
p. 163-
1 p.
|
artikel
|
| 130 |
PGD2: IMPROVED DRUG COMPLIANCE USING EDUCATION AFFECTS MEDICAL UTILIZATION AND QUALITY OF LIFE FOR PEPTIC ULCER DISEASE PATIENTS
|
Addiego, J
|
|
2000
|
3 |
2 |
p. 152-
1 p.
|
artikel
|
| 131 |
PGD1: OVER-THE-COUNTER NSAID USE AND Gl TOXICITY
|
Bloom, BS
|
|
2000
|
3 |
2 |
p. 152-
1 p.
|
artikel
|
| 132 |
PGD4: THE CLINICAL AND ECONOMIC IMPACT OF COMPETING MANAGEMENT STRATEGIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD)
|
Ofman, J
|
|
2000
|
3 |
2 |
p. 153-
1 p.
|
artikel
|
| 133 |
PHH9: A MANAGED CARE VALIDATION PROGRAM FOR A PHARMACOECONOMIC MODEL OF MAJOR DEPRESSION
|
Casciano, J
|
|
2000
|
3 |
2 |
p. 80-
1 p.
|
artikel
|
| 134 |
PHH17: BIPOLAR DISORDER DRUG USE PATTERNS AND COMPLIANCE IN MEDI-CAL POPULATION
|
Li, J
|
|
2000
|
3 |
2 |
p. 83-
1 p.
|
artikel
|
| 135 |
PHH7: COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN CHRONIC SCHIZOPHRENIA
|
Karki, SD
|
|
2000
|
3 |
2 |
p. 79-80
2 p.
|
artikel
|
| 136 |
PHT17: DEALING WITH SKEWED DATA: AN EXAMPLE USING ASTHMA-RELATED COSTS OF MEDICAID CLIENTS
|
Rascati, KL
|
|
2000
|
3 |
2 |
p. 107-
1 p.
|
artikel
|
| 137 |
PHT8: DEVELOPMENT OF A NEW SCORING OF THE WOMEN'S HEALTH QUESTIONNAIRE (WHQ)
|
Girod, I
|
|
2000
|
3 |
2 |
p. 103-104
2 p.
|
artikel
|
| 138 |
PHT14: IMPROVING THE EVIDENCE BASE OF ECONOMIC ANALYSES
|
Coyle, D
|
|
2000
|
3 |
2 |
p. 106-
1 p.
|
artikel
|
| 139 |
PHT4: METHODOLOGICAL ISSUES IN ESTIMATING DISEASE PROGRESSION: IS MARKOV MODEL THE BEST METHOD?
|
Shih, YCT
|
|
2000
|
3 |
2 |
p. 102-
1 p.
|
artikel
|
| 140 |
PHT7: THE FRENCH HEALTH UTILITIES INDEX MARK 3
|
Le Galès, C
|
|
2000
|
3 |
2 |
p. 103-
1 p.
|
artikel
|
| 141 |
PHV14: A MULTINATIONAL PHARMACOECONOMIC EVALUATION OF THE SEVEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
|
Arikian, S
|
|
2000
|
3 |
2 |
p. 121-122
2 p.
|
artikel
|
| 142 |
PHV16: AN UNUSUAL ECONOMIC EVALUATION OF EFAVIRENZ COMPARED TO INDINAVIR
|
Migliaccio-Walle, K
|
|
2000
|
3 |
2 |
p. 122-
1 p.
|
artikel
|
| 143 |
PHV15: CLINICAL AND ECONOMIC BENEFITS OF THE PNEUMOCOCCAL CONJUGATE VACCINE IN CHILDREN
|
Oster, G
|
|
2000
|
3 |
2 |
p. 122-
1 p.
|
artikel
|
| 144 |
PHV13: COST ANALYSIS OF CEFTRIAXONE VERSUS CEFTRIAXONE PLUS MACROLIDE TREATMENT FOR PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP)
|
Truong, K
|
|
2000
|
3 |
2 |
p. 121-
1 p.
|
artikel
|
| 145 |
PHV20: COST-EFFECTIVENESS ANALYSIS OF LAMIVUDINE TREATMENT IN CHRONIC HEPATITIS B
|
Yeh, YC
|
|
2000
|
3 |
2 |
p. 124-
1 p.
|
artikel
|
| 146 |
PHV11: COST-MINIMIZATION ANALYSIS OF AZITHROMYCIN IV/PO VERSUS CEFUROXIME IV/PO ± ERYTHROMYCIN IV/PO FOR COMMUNITY-ACQUIRED PNEUMONIA
|
Wong, AH
|
|
2000
|
3 |
2 |
p. 120-121
2 p.
|
artikel
|
| 147 |
PHV9: COST OF TREATING HISPANIC PATIENTS WITH AIDS IN US HOSPITALS
|
O'Brien, J
|
|
2000
|
3 |
2 |
p. 120-
1 p.
|
artikel
|
| 148 |
PHV30: COSTS AND OUTCOMES OF A RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS PROGRAM IN A MEDICAID MANAGED CARE ORGANIZATION
|
Schaffer, M
|
|
2000
|
3 |
2 |
p. 127-128
2 p.
|
artikel
|
| 149 |
PHV27: COSTS AND OUTCOMES OF TREATING FEBRILE NEUTROPENIA IN NINE EUROPEAN COUNTRIES
|
Flynn, J
|
|
2000
|
3 |
2 |
p. 126-
1 p.
|
artikel
|
| 150 |
PHV24: DISCRIMINATIVE ABILITY OF THE SF-12 IN A SAMPLE OF PERSONS WITH HIV
|
Delate, T
|
|
2000
|
3 |
2 |
p. 125-
1 p.
|
artikel
|
| 151 |
PHV6: ECONOMIC EVALUATION OF A SAFETY DEVICE FOR SUBCUTANEOUS INJECTIONS OF LOW MOLECULAR WEIGHT HEPARIN (LMWH)
|
Durand-Zaleski, I
|
|
2000
|
3 |
2 |
p. 119-
1 p.
|
artikel
|
| 152 |
PHV5: EFFECTIVENESS AND COSTS OF ANTIBIOTICS IN THE AMBULATORY TREATMENT OF RESPIRATORY TRACT INFECTIONS
|
Laurier, C
|
|
2000
|
3 |
2 |
p. 118-
1 p.
|
artikel
|
| 153 |
PHV26: EFFECTIVENESS OF ANTIBIOTIC PRESCRIBING AND PATIENT OUTCOMES IN A COMMUNITY SETTING: THE AUSTRALIAN EXPERIENCE
|
Beilby, J
|
|
2000
|
3 |
2 |
p. 126-
1 p.
|
artikel
|
| 154 |
PHV4: HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH FOUR CATEGORIES OF SKIN ULCERS IN NEW MEXICO MEDICAID PATIENTS
|
Kumar, RN
|
|
2000
|
3 |
2 |
p. 118-
1 p.
|
artikel
|
| 155 |
PHV19: IMPACT OF ANTIBIOTIC CHOICE ON COSTS, OUTPATIENT VISITS, AND 28-DAY OUTCOMES FOR COMMUNITY-ACQUIRED PNEUMONIA PATIENTS
|
Bell, TJ
|
|
2000
|
3 |
2 |
p. 123-
1 p.
|
artikel
|
| 156 |
PHV12: MANAGEMENT STRATEGIES FOR RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA IN THE TREATMENT OF HEPATITIS C: CLINICAL AND ECONOMIC IMPLICATIONS
|
Devine, EB
|
|
2000
|
3 |
2 |
p. 121-
1 p.
|
artikel
|
| 157 |
PHV7: MANAGING PNEUMOCYSTOSIS: THE COST OF HOSPITALIZATION IN THE US
|
O'Brien, J
|
|
2000
|
3 |
2 |
p. 119-
1 p.
|
artikel
|
| 158 |
PHV3: MODELLING A COST-OF-ILLNESS STUDY TO EVALUATE THE BURDEN OF INFLUENZA IN ITALY
|
Aimola, A
|
|
2000
|
3 |
2 |
p. 117-118
2 p.
|
artikel
|
| 159 |
PHV1O: A PRELIMINARY STUDY: THE PHARMACOECONOMIC PROFILE OF ANTIBIOTIC USE IN TURKEY
|
Sapci, H
|
|
2000
|
3 |
2 |
p. 120-
1 p.
|
artikel
|
| 160 |
PHV23: PATIENT ADHERENCE WITH MULTI-DRUG HIV THERAPY: VARIATIONS IN ADHERENCE AND CORRELATION WITH HIV RNA LEVELS
|
Farmer, K.C
|
|
2000
|
3 |
2 |
p. 125-
1 p.
|
artikel
|
| 161 |
PHV17: PRELIMINARY ASSESSMENT OF THE ECONOMIC VALUE OF ADULT PERTUSSIS BOOSTER VACCINATION
|
Botteman, MF
|
|
2000
|
3 |
2 |
p. 122-123
2 p.
|
artikel
|
| 162 |
PHV21: PRELIMINARY ASSESSMENT OF THE ECONOMIC VALUE OF PERTUSSIS BOOSTER VACCINATION OF HOSPITAL STAFF
|
Botteman, MF
|
|
2000
|
3 |
2 |
p. 124-
1 p.
|
artikel
|
| 163 |
PHV25: QUALITY OF LIFE OF ADULT PATIENTS TREATED FOR A RESPIRATORY TRACT INFECTION
|
Lachaine, J
|
|
2000
|
3 |
2 |
p. 125-126
2 p.
|
artikel
|
| 164 |
PHV18: SAFETY-NET HOSPITAL PERSPECTIVE: COST-EFFECTIVENESS OF TREATMENT FOR HEPATITIS C
|
Singer, ME
|
|
2000
|
3 |
2 |
p. 123-
1 p.
|
artikel
|
| 165 |
PHV2: THE BURDEN OF RESPIRATORY SYNCTIAL VIRUS (RSV) HOSPITALIZATIONS IN THE US
|
Howard, TS
|
|
2000
|
3 |
2 |
p. 117-
1 p.
|
artikel
|
| 166 |
PHV8: UNCOMPLICATED ACUTE PYELONEPHRITIS IN ADULT WOMEN: INPATIENT VERSUS OUTPATIENT THERAPY -ECONOMIC COMPARISON
|
Tibi-Lévy, Y
|
|
2000
|
3 |
2 |
p. 119-120
2 p.
|
artikel
|
| 167 |
PHV22: UTILIZATION AND COST-EFFECTIVENESS OF ANTIMICROBIALS IN COMMUNITY-ACQUIRED PNEUMONIA
|
Karpov, O
|
|
2000
|
3 |
2 |
p. 124-125
2 p.
|
artikel
|
| 168 |
PHV1: UTILIZATION OF INTENSIVE CARE AND HOSPITAL DAYS AND OUTCOME IN PATIENTS WITH SEVERE SEPSIS: THE SELECT II REGISTRY
|
Formica, CA
|
|
2000
|
3 |
2 |
p. 117-
1 p.
|
artikel
|
| 169 |
PHV29: VARIABILITY IN THE CRITERIA FOR EARLY SWITCH AND EARLY DISCHARGE IN COMMUNITY-ACQUIRED PNEUMONIA: A SYSTEMATIC REVIEW OF THE LITERATURE
|
Rhew, DC
|
|
2000
|
3 |
2 |
p. 127-
1 p.
|
artikel
|
| 170 |
PHW4: MEASUREMENT PROPERTIES OF QUALITY OF LIFE INSTRUMENTS IN ERECTILE DYSFUNCTION (ED): A REVIEW OF PUBLISHED RESULTS
|
Emery, MP
|
|
2000
|
3 |
2 |
p. 99-100
2 p.
|
artikel
|
| 171 |
PMH40: ACCESS TO NEW MEDICATIONS TO TREAT SCHIZOPHRENIA
|
Mark, T
|
|
2000
|
3 |
2 |
p. 92-
1 p.
|
artikel
|
| 172 |
PMH3: ALZHEIMER'S DISEASE COST OF CARE IN MANAGED CARE
|
Richards, KM
|
|
2000
|
3 |
2 |
p. 78-
1 p.
|
artikel
|
| 173 |
PMH19: ANTIPSYCHOTIC DRUG USE PATTERNS AND THE COST OF TREATING SCHIZOPHRENIA: DATA FROM THE MEDICAID PROGRAMS OF ALABAMA, GEORGIA, KENTUCKY, AND MICHIGAN
|
Lyu, RR
|
|
2000
|
3 |
2 |
p. 84-
1 p.
|
artikel
|
| 174 |
PMH4: ANTIPSYCHOTIC MEDICATION TREATMENT PATTERNS AND ASSOCIATED COST OF CARE OF PATIENTS WITH SCHIZOPHRENIA
|
Loosbrock, DL
|
|
2000
|
3 |
2 |
p. 78-
1 p.
|
artikel
|
| 175 |
PMH22: CAN THE BRIEF “QOLWM” DISCRIMINATE AMONG MIGRAINEURS IN THE COMMUNITY?
|
Cramer, JA
|
|
2000
|
3 |
2 |
p. 85-
1 p.
|
artikel
|
| 176 |
PMH26: CHANGE IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA TAKING ANTIPSYCHOTIC AGENTS
|
Edell, WS
|
|
2000
|
3 |
2 |
p. 86-87
2 p.
|
artikel
|
| 177 |
PMH34: CHARACTERIZATION AND ASSESSMENT OF DEPRESSION IN A CHRONIC NON-MALIGNANT PAIN POPULATION USING TWO DIFFERENT METHODOLOGIES IN A CLAIMS DATABASE
|
Mody, SH
|
|
2000
|
3 |
2 |
p. 90-
1 p.
|
artikel
|
| 178 |
PMH21: COMMUNITY PHARMACIST ASSESSMENT OF THE QUALITY OF LIFE OF TREATED AMBULATORY DEPRESSED PATIENTS
|
Taylor, AT
|
|
2000
|
3 |
2 |
p. 85-
1 p.
|
artikel
|
| 179 |
PMH36: CONFORMANCE WITH ANTIPSYCHOTIC DRUG THERAPY GUIDELINES FOR TREATING SCHIZOPHRENIA IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM
|
Luo, M
|
|
2000
|
3 |
2 |
p. 90-91
2 p.
|
artikel
|
| 180 |
PMH8: COST-EFFECTIVENESS OF STRATIFIED CARE IN THE MANAGEMENT OF MIGRAINE
|
Rapoport, A
|
|
2000
|
3 |
2 |
p. 80-
1 p.
|
artikel
|
| 181 |
PMH35: ECONOMIC OUTCOMES WITH NEWER ANTIDEPRESSANTS FOR THE TREATMENT OF DEPRESSION IN A COMMERCIALLY-INSURED POPULATION
|
Mukherjee, R
|
|
2000
|
3 |
2 |
p. 90-
1 p.
|
artikel
|
| 182 |
PMH2: ESTIMATED COSTS OF TREATMENT FOR BIPOLAR AFFECTIVE DISORDER IN A LARGE EMPLOYER DATABASE
|
Johnstone, BM
|
|
2000
|
3 |
2 |
p. 77-78
2 p.
|
artikel
|
| 183 |
PMH37: EVALUATING HEALTHCARE RESOURCE UTILIZATION IN A POPULATION OF MIGRAINE PATIENTS USING SUMATRIPTAN AND NON-SUMATRIPTAN PHARMACEUTICALS
|
Joish, VN
|
|
2000
|
3 |
2 |
p. 91-
1 p.
|
artikel
|
| 184 |
PMH39: HEALTH CARE BURDEN AND COST OF PARKINSON'S DISEASE
|
Wilson, L
|
|
2000
|
3 |
2 |
p. 92-
1 p.
|
artikel
|
| 185 |
PMH23: HOW MUCH CHANGE IN QUALITY OF LIFE AND SYMPTOM SCORES REPRESENTS A DETECTABLE DIFFERENCE FOR SCHIZOPHRENIA PATIENTS?
|
Cramer, JA
|
|
2000
|
3 |
2 |
p. 85-86
2 p.
|
artikel
|
| 186 |
PMH20: MEDICAL RESOURCES CONSUMPTION BY PATIENTS WITH CHRONIC AND BREAKTHROUGH PAIN
|
Noe, L
|
|
2000
|
3 |
2 |
p. 84-85
2 p.
|
artikel
|
| 187 |
PMH30: MODELING LENGTH OF PRESCRIPTION THERAPY FOR DEPRESSION PATIENTS
|
Billingsley, J-K
|
|
2000
|
3 |
2 |
p. 88-
1 p.
|
artikel
|
| 188 |
PMH33: NEUROLEPTIC DRUG EXPOSURE AND TARDIVE DYSKINESIA: A RECORDS-BASED CASE-CONTROL STUDY
|
Marshall, DL
|
|
2000
|
3 |
2 |
p. 89-
1 p.
|
artikel
|
| 189 |
PMH1O: A MODEL TO PERFORM ECONOMIC EVALUATIONS OF INTERVENTIONS FOR ACUTE MUSCULAR LOW BACK PAIN
|
Neighbors, D
|
|
2000
|
3 |
2 |
p. 80-81
2 p.
|
artikel
|
| 190 |
PMH41: PATTERNS OF ANTIDEPRESSANT USE AND CONCOMITANT PSYCHOTHERAPEUTIC AGENTS
|
Fulop, G
|
|
2000
|
3 |
2 |
p. 92-93
2 p.
|
artikel
|
| 191 |
PMH28: QUALITY OF LIFE DIFFERENCES BETWEEN PATIENTS WITH EPISODIC AND TRANSFORMED MIGRAINE
|
Meletiche, DM
|
|
2000
|
3 |
2 |
p. 87-88
2 p.
|
artikel
|
| 192 |
PMH32: QUANTIFYING THE ECONOMIC IMPACT OF POTENTIAL DRUG INTERACTIONS IN THE TREATMENT OF DEPRESSION
|
Bourne, MJ
|
|
2000
|
3 |
2 |
p. 89-
1 p.
|
artikel
|
| 193 |
PMH1: RECENT TRENDS IN THE COST OF CARE FOR PATIENTS WITH SCHIZOPHRENIA
|
Johnstone, BM
|
|
2000
|
3 |
2 |
p. 77-
1 p.
|
artikel
|
| 194 |
PMH38: RESPONSE TO NEFAZODONE, CBASP, AND COMBINED THERAPY: IMPLICATIONS FOR CHRONIC DEPRESSION SEVERITY, FUNCTIONAL STATUS AND ECONOMIC OUTCOMES
|
Crown, WH
|
|
2000
|
3 |
2 |
p. 91-92
2 p.
|
artikel
|
| 195 |
PMH5: THE EFFECT OF RIVASTIGMINE ON THE DIRECT AND INDIRECT COSTS OF ALZHEIMER'S DISEASE
|
Brooks, E
|
|
2000
|
3 |
2 |
p. 79-
1 p.
|
artikel
|
| 196 |
PMH12: THE EFFICIENCY OF DRUG TREATMENT IN FIRST EPISODE SCHIZOPHRENIA: TREATMENT GUIDELINES IN THE UK
|
Davies, LM
|
|
2000
|
3 |
2 |
p. 81-
1 p.
|
artikel
|
| 197 |
PMH42: THE IMPACT OF ADDING SSRI ANTIDEPRESSANTS TO THE MEDICAID FORMULARY IN CALIFORNIA
|
McCombs, JS
|
|
2000
|
3 |
2 |
p. 93-
1 p.
|
artikel
|
| 198 |
PMH29: THE IMPACT OF AN OVER-THE-COUNTER MIGRAINE MEDICATION ON PATIENT QUALITY OF LIFE
|
Burk, C
|
|
2000
|
3 |
2 |
p. 88-
1 p.
|
artikel
|
| 199 |
PMH27: THE IMPACT OF DEPRESSION ON HEALTH-RELATED QUALITY OF LIFE (HRQL)
|
Mody, SH
|
|
2000
|
3 |
2 |
p. 87-
1 p.
|
artikel
|
| 200 |
PMH25: THE IMPACT OF SCHIZOPHRENIA ON HEALTH-RELATED QUALITY OF LIFE (HRQL) FOR PATIENTS ADMITTED TO PSYCHIATRIC UNITS OF GENERAL ACUTE CARE HOSPITALS
|
Durkin, MB
|
|
2000
|
3 |
2 |
p. 86-
1 p.
|
artikel
|
| 201 |
PMH24: TRANSLATIONS OF THE MIGRAINE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE (MSQ): A PSYCHOMETRIC COMPARISON BETWEEN THE ENGLISH, FINNISH, DUTCH, HUNGARIAN, AND SPANISH TRANSLATIONS
|
Grossman, PR
|
|
2000
|
3 |
2 |
p. 86-
1 p.
|
artikel
|
| 202 |
PMH11: TREATMENT GUIDELINES COMPARED TO CLINICAL PRACTICE FOR ACUTE MUSCULAR LOW BACK PAIN
|
Earnshaw, SR
|
|
2000
|
3 |
2 |
p. 81-
1 p.
|
artikel
|
| 203 |
PMH31: TREATMENT OF CHILDHOOD DEPRESSION IN A MANAGED CARE POPULATION
|
McLaughlin, T
|
|
2000
|
3 |
2 |
p. 88-89
2 p.
|
artikel
|
| 204 |
PMH16: USE OF ATYPICAL ANTIPSYCHOTIC MEDICATIONS IN A VETERANS POPULATION
|
Hudson, T
|
|
2000
|
3 |
2 |
p. 83-
1 p.
|
artikel
|
| 205 |
PMH18: USE OF NONBARBITURATE SEDATIVE/ HYPNOTIC AGENTS IN AN AMBULATORY POPULATION
|
Hornquist, M
|
|
2000
|
3 |
2 |
p. 83-84
2 p.
|
artikel
|
| 206 |
PMH14: USE OF OLANZAPINE AND RISPERIDONE AT BASELINE IN A PROSPECTIVE STUDY OF THE COURSE OF TREATMENT FOR SCHIZOPHRENIA
|
Johnstone, BM
|
|
2000
|
3 |
2 |
p. 82-
1 p.
|
artikel
|
| 207 |
PMH15: UTILIZATION OF ANTIPSYCHOTIC MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIA IN A MANAGED CARE POPULATION
|
Nichol, MB
|
|
2000
|
3 |
2 |
p. 82-83
2 p.
|
artikel
|
| 208 |
PMT31: AN ASSESSMENT OF COST-UTILITY OF PATIENTS FROM SF-36 SCORES USING THE BEAVER DAM HEALTH OUTCOMES STUDY METHOD
|
Nadesan, B
|
|
2000
|
3 |
2 |
p. 112-
1 p.
|
artikel
|
| 209 |
PMT34: ASSESSING PHYSICIAN PRACTICE PROFITABILITY USING AN ACTIVITY BASED COSTING MODEL
|
Stephens, JM
|
|
2000
|
3 |
2 |
p. 113-
1 p.
|
artikel
|
| 210 |
PMT9: ASSESSING THE COST-EFFECTIVENESS RATIO OF A NEW ANTI-PLATELET AGENT: METHODOLOGIC ISSUES
|
Levy, E
|
|
2000
|
3 |
2 |
p. 104-
1 p.
|
artikel
|
| 211 |
PMT37: BENEFITS OF EARLY MODELING IN DRUG DISCOVERY
|
Stevenson, M
|
|
2000
|
3 |
2 |
p. 114-
1 p.
|
artikel
|
| 212 |
PMT18: BIAS ARISING FROM MISSING DATA IN A RETROSPECTIVE STUDY OF THE OUTCOMES OF INTRA-ABDOMINAL INFECTIONS
|
Davey, P
|
|
2000
|
3 |
2 |
p. 107-
1 p.
|
artikel
|
| 213 |
PMT24: “CAMOUFLAGED SAMPLING” USING BC MINISTRY OF HEALTH DATA: A METHOD OF RECRUITING SUBJECTS WHILE PRESERVING DATA PRIVACY
|
Maclure, M
|
|
2000
|
3 |
2 |
p. 109-110
2 p.
|
artikel
|
| 214 |
PMT25: COMPARATIVE ECONOMETRIC MODELS OF MEDICAL COSTS
|
Wu, Q
|
|
2000
|
3 |
2 |
p. 110-
1 p.
|
artikel
|
| 215 |
PMT12: DATA REQUIREMENTS OF SECOND-GENERATION ECONOMIC MODELS IN HIV/AIDS
|
Simpson, KN
|
|
2000
|
3 |
2 |
p. 105-
1 p.
|
artikel
|
| 216 |
PMT21: DERIVING HEALTH UTILITIES FROM EFFICACY OUTCOME SCALES IN ALZHEIMER'S DISEASE (AD)
|
Lanctot, KL
|
|
2000
|
3 |
2 |
p. 108-
1 p.
|
artikel
|
| 217 |
PMT5: DEVELOPMENT OF MULTI-LANGUAGE PATIENT OUTCOME ASSESSMENTS
|
Rente, AM
|
|
2000
|
3 |
2 |
p. 102-
1 p.
|
artikel
|
| 218 |
PMT16: ESTIMATION OF ANNUAL CARDIOVASCULAR RISK IN PILOTS
|
Milne, RJ
|
|
2000
|
3 |
2 |
p. 106-107
2 p.
|
artikel
|
| 219 |
PMT26: FIELLER'S INTERVAL, ITS EXTENSIONS AND THEIR APPLICATIONS IN COST-EFFECTIVENESS ANALYSES
|
Jiang, GJ
|
|
2000
|
3 |
2 |
p. 110-
1 p.
|
artikel
|
| 220 |
PMT28: HEALTH RELATED QUALITY OF LIFE IN A GENERAL SWEDISH POPULATION WITH A GENDER PERSPECTIVE
|
Lundberg, L
|
|
2000
|
3 |
2 |
p. 111-
1 p.
|
artikel
|
| 221 |
PMT33: LINGUISTIC VALIDATION OF THE VASCULAR QUALITY OF LIFE QUESTIONNAIRE (VASCUQOL) IN 8 LANGUAGES
|
Conway, K
|
|
2000
|
3 |
2 |
p. 113-
1 p.
|
artikel
|
| 222 |
PMT36: LINGUISTIC VALIDATION OF THE WORK LIMITATIONS QUESTIONNAIRE (WLQ)
|
Conway, K
|
|
2000
|
3 |
2 |
p. 114-
1 p.
|
artikel
|
| 223 |
PMT11: METHODOLOGY FOR IDENTIFYING PATIENTS AT HIGH RISK FOR OSTEOPOROTIC FRACTURES WITHIN A MANAGED CARE ENVIRONMENT
|
Heaton, AH
|
|
2000
|
3 |
2 |
p. 104-105
2 p.
|
artikel
|
| 224 |
PMT6: MONITORING THE GATEKEEPER: METHODOLOGIES FOR THE DEVELOPMENT OF PROCESS AND OUTCOME MEASURES FOR THE EVALUATION OF IRBS
|
Gold, KF
|
|
2000
|
3 |
2 |
p. 103-
1 p.
|
artikel
|
| 225 |
PMT23: MONTE-CARLO SIMULATION AS AN ALTERNATIVE TECHNIQUE IN ADDRESSING THE UNIT COST VARIABILITY ISSUE
|
Tran, G
|
|
2000
|
3 |
2 |
p. 109-
1 p.
|
artikel
|
| 226 |
PMT19: NON-RANDOMIZED STUDIES COMPARING OLANZAPINE AND RISPERIDONE: BASELINE SIMILARITIES AND DIFFERENCES
|
Gibson, PJ
|
|
2000
|
3 |
2 |
p. 107-108
2 p.
|
artikel
|
| 227 |
PMT1O: MODELLING ISSUES: FIRST EPISODE SCHIZOPHRENIA
|
Davies, LM
|
|
2000
|
3 |
2 |
p. 104-
1 p.
|
artikel
|
| 228 |
PMT3: PREDICTING DRUG SPENDING: UPDATE AND EVALUATION OF A REVISED CHRONIC DISEASE SCORE
|
Zhao, Z
|
|
2000
|
3 |
2 |
p. 101-102
2 p.
|
artikel
|
| 229 |
PMT30: PREFERENCE BASED INDEX FROM THE SF-12
|
Sengupta, N
|
|
2000
|
3 |
2 |
p. 111-112
2 p.
|
artikel
|
| 230 |
PMT2: RELIABILITY OF PRESCRIPTION CLAIMS DATA FOR HEALTH CARE RESEARCH
|
Thomas, J
|
|
2000
|
3 |
2 |
p. 101-
1 p.
|
artikel
|
| 231 |
PMT29: THE INFLUENCE OF STATISTICAL ERRORS ON THE COST-EFFECTIVENESS OF TREATMENTS FOLLOWING A PHASE-MI CLINICAL TRIAL
|
Kamae, I
|
|
2000
|
3 |
2 |
p. 111-
1 p.
|
artikel
|
| 232 |
PMT20: THE USE OF ECONOMIC ANALYSES IN PRACTICE GUIDELINE DEVELOPMENT
|
Wallace, JF
|
|
2000
|
3 |
2 |
p. 108-
1 p.
|
artikel
|
| 233 |
PMT1: THE VALUE OF OBSERVATIONAL DATASETS IN THE ECONOMIC EVALUATION OF PHARMACEUTICALS: UK OBSERVATIONS
|
Tolley, K
|
|
2000
|
3 |
2 |
p. 100-101
2 p.
|
artikel
|
| 234 |
PMT13: TRANSFERING THE RESULTS FROM ECONOMIC EVALUATIONS: THE USE OF BASILIXIMAB IN TRANSPLANT PATIENTS
|
Lee, KM
|
|
2000
|
3 |
2 |
p. 105-106
2 p.
|
artikel
|
| 235 |
PMT22: TREATMENT SATISFACTION IN OUTCOMES RESEARCH: AN OVERVIEW OF STUDY MEASURES
|
Wang, AY
|
|
2000
|
3 |
2 |
p. 108-109
2 p.
|
artikel
|
| 236 |
PMT32: UTILITY ESTIMATION USING THE EQ-5D: EXPERT PANEL DATA AND ALTERNATIVE METHODS OF SYNTHESIS
|
Smith, D
|
|
2000
|
3 |
2 |
p. 112-
1 p.
|
artikel
|
| 237 |
PMT15: VALIDATION OF FRAMINGHAM REGRESSION EQUATIONS FOR LOCAL USE
|
Milne, RJ
|
|
2000
|
3 |
2 |
p. 106-
1 p.
|
artikel
|
| 238 |
PMT35: VALUING NON-WORKPLACE PRODUCTIVITY LOST IN MIGRAINEURS: HUMAN CAPITAL APPROACH AND REPLACEMENT COST METHOD
|
Kim, SS
|
|
2000
|
3 |
2 |
p. 113-114
2 p.
|
artikel
|
| 239 |
PMW5: A PHARMACOECONOMIC EVALUATION OF HORMONE REPLACEMENT THERAPY IN THE UNITED KINGDOM AND BELGIUM
|
Doyle, JJ
|
|
2000
|
3 |
2 |
p. 100-
1 p.
|
artikel
|
| 240 |
PMW2: DOES TESTOSTERONE AFFECT HEALTH-RELATED QUALITY OF LIFE IN HEALTHY, ELDERLY MALES?—A PILOT STUDY
|
Reddy, P
|
|
2000
|
3 |
2 |
p. 98-99
2 p.
|
artikel
|
| 241 |
PMW6: MATCHING VA UROLOGISTS' PREFERENCES IN THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA WITH CLINICAL PRACTICE GUIDELINES
|
Fernandes, AW
|
|
2000
|
3 |
2 |
p. 100-
1 p.
|
artikel
|
| 242 |
PMW3: PRESCRIPTION DRUG USE DURING PREGNANCY: A CLAIMS ANALYSIS
|
Zenk, HA
|
|
2000
|
3 |
2 |
p. 99-
1 p.
|
artikel
|
| 243 |
PMW1: THE NEED FOR A QUALITY-OF-LIFE INSTRUMENT FOR ERECTILE DYSFUNCTION: A SYSTEMATIC REVIEW OF THE LITERATURE
|
Lenderking, WR
|
|
2000
|
3 |
2 |
p. 98-
1 p.
|
artikel
|
| 244 |
PNH6: PHARMACOECONOMIC ANALYSES OF DEPOT NEUROLEPTIC TREATMENT IN NATURAL SETTING
|
Gurovich, I
|
|
2000
|
3 |
2 |
p. 79-
1 p.
|
artikel
|
| 245 |
POS4: COST-EFFECTIVENESS OF SCREENING FOR OSTEOPOROSIS IN ELDERLY WOMEN
|
Du, HV
|
|
2000
|
3 |
2 |
p. 95-
1 p.
|
artikel
|
| 246 |
POS2: INTEREST OF THE SIMPLE CALCULATED OSTEOPOROSIS RISK ESTIMATION (SCORE) TOOL FOR A MORE RATIONAL USE OF BONE DENSITOMETRY
|
BenSedrine, W
|
|
2000
|
3 |
2 |
p. 94-
1 p.
|
artikel
|
| 247 |
POS5: PREVALENCE OF PHARMACOTHERAPY FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS IN A MANAGED CARE ENVIRONMENT
|
Hall, J
|
|
2000
|
3 |
2 |
p. 95-
1 p.
|
artikel
|
| 248 |
POS1: THE BURDEN OF OSTEOPOROSIS TO THE STATE OF FLORIDA: PROJECTIONS FOR 2000-2010
|
Burge, RT
|
|
2000
|
3 |
2 |
p. 93-94
2 p.
|
artikel
|
| 249 |
POS3: THE SIMPLE CALCULATED OSTEOPOROSIS RISK ESTIMATION (SCORE) DOES NOT ALLOW IDENTIFICATION OF BELGIAN WOMEN WITH A HIGH RISK OF OSTEOPOROSIS
|
BenSedrine, W
|
|
2000
|
3 |
2 |
p. 94-95
2 p.
|
artikel
|
| 250 |
PRN4: ASSESSING QUALITY OF LIFE IN ROUTINE CLINICAL PRACTICE: A PILOT STUDY IN PATIENTS WITH RENAL DISEASE
|
Wild, D
|
|
2000
|
3 |
2 |
p. 140-141
2 p.
|
artikel
|
| 251 |
PRN3: COST ANALYSIS OF “OPTIMAL” US DIALYSIS MODALITY UTILIZATION
|
Just, PM
|
|
2000
|
3 |
2 |
p. 140-
1 p.
|
artikel
|
| 252 |
PRN2: COST-EFFECTIVENESS OF BASILIXIMAB, DACLIZUMAB, AND OKT3 AS INDUCTION AGENTS IN KIDNEY TRANSPLANTATION
|
Shin, GP
|
|
2000
|
3 |
2 |
p. 140-
1 p.
|
artikel
|
| 253 |
PRN6: DEVELOPING A SPECIFIC HRQL INSTRUMENT FOR OVERACTIVE BLADDER
|
Coyne, K
|
|
2000
|
3 |
2 |
p. 141-
1 p.
|
artikel
|
| 254 |
PRN8: MEDICAL CARE OF OVERACTIVE BLADDER IN ELDERLY MEDICARE PATIENTS
|
Jensen, GA
|
|
2000
|
3 |
2 |
p. 142-
1 p.
|
artikel
|
| 255 |
PRN1: OVERACTIVE BLADDER COST OF ILLNESS: ANALYSIS OF MEDI-CAL CLAIMS
|
Bailey, KL
|
|
2000
|
3 |
2 |
p. 139-140
2 p.
|
artikel
|
| 256 |
PRN5: QUALITY OF LIFE AND HEALTH CARE RESOURCE UTILIZATION IN OVERACTIVE BLADDER PATIENTS WITH URGE INCONTINENCE
|
Rosner, AJ
|
|
2000
|
3 |
2 |
p. 141-
1 p.
|
artikel
|
| 257 |
PRN7: RELIABILITY OF REPORTING ON COPING STRATEGIES AND IMPACT OF OVERACTIVE BLADDER
|
Stewart, WF
|
|
2000
|
3 |
2 |
p. 141-142
2 p.
|
artikel
|
| 258 |
PRN9: THE INFLUENCE OF PHARMACEUTICAL CARE SERVICES ON THE BLOOD PRESSURE OF RENAL TRANSPLANT PATIENTS
|
Chisholm, MA
|
|
2000
|
3 |
2 |
p. 142-
1 p.
|
artikel
|
| 259 |
PRS10: ANNUAL COST OF TREATING ASTHMA IN A MANAGED CARE POPULATION
|
Yazdani, C
|
|
2000
|
3 |
2 |
p. 146-
1 p.
|
artikel
|
| 260 |
PRS6: CLASSIFYING ASTHMA SEVERITY BASED ON PRESCRIPTION DRUG CLAIMS
|
Leahy, MJ
|
|
2000
|
3 |
2 |
p. 144-145
2 p.
|
artikel
|
| 261 |
PRS1: DIRECT AND INDIRECT COSTS OF ASTHMA TO AN EMPLOYER
|
Birnbaum, HG
|
|
2000
|
3 |
2 |
p. 143-
1 p.
|
artikel
|
| 262 |
PRS7: DRIVERS OF DIAGNOSIS OF OBSTRUCTIVE LUNG DISEASE, BY STAGE OF SEVERITY
|
Silberman, C
|
|
2000
|
3 |
2 |
p. 145-
1 p.
|
artikel
|
| 263 |
PRS8: ECONOMIC OUTCOMES OF STEROID INHALER USE PATTERNS IN A MANAGED CARE ORGANIZATION
|
White, TJ
|
|
2000
|
3 |
2 |
p. 145-
1 p.
|
artikel
|
| 264 |
PRS4: IDENTIFYING PREDICTORS OF THE ASTHMA-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE FOR NATIVE-AMERICAN ADULTS (AQLQ-NAA)
|
Gupchup, GV
|
|
2000
|
3 |
2 |
p. 144-
1 p.
|
artikel
|
| 265 |
PRS2: IMPACT OF A TARGETED ASTHMA INTERVENTION PROGRAM ON TREATMENT COSTS
|
Suh, DC
|
|
2000
|
3 |
2 |
p. 143-
1 p.
|
artikel
|
| 266 |
PRS5: IMPACT OF INHALED CORTICOSTEROIDS (FLUTICASONE PROPIONATE) ON ECONOMIC OUTCOMES IN A MANAGED CARE ENVIRONMENT
|
Oates, V
|
|
2000
|
3 |
2 |
p. 144-
1 p.
|
artikel
|
| 267 |
PRS9: PREDICTORS OF HOSPITALIZATION AND EMERGENCY ROOM USE IN A MEDICAID MANAGED CARE ASTHMATIC POPULATION
|
Drabinski, AM
|
|
2000
|
3 |
2 |
p. 146-
1 p.
|
artikel
|
| 268 |
PRS3: TRENDS IN THE USE OF β-AGONIST MEDICATIONS IN BRITISH COLUMBIA: AN ANALYSIS OF BC PHARMACARE DATA
|
Lynd, LD
|
|
2000
|
3 |
2 |
p. 143-144
2 p.
|
artikel
|
| 269 |
PSC7: POSTOPERATIVE PAIN RELIEF, INTERFERENCE WITH ACTIVITIES, AND SATISFACTION: PRELIMINARY RESULTS
|
Strassels, S
|
|
2000
|
3 |
2 |
p. 149-
1 p.
|
artikel
|
| 270 |
PSG11: COST ANALYSIS OF INHALED AGENTS IN CANADIAN PEDIATRIC HOSPITALS
|
Bussières, JF
|
|
2000
|
3 |
2 |
p. 150-
1 p.
|
artikel
|
| 271 |
PSG14: COST-EFFECTIVE STRATEGIES: ASSESSING PHARMACISTS INTERVENTION IN A COMMUNITY HOSPITAL INTENSIVE CARE UNIT
|
Dilanchian, P
|
|
2000
|
3 |
2 |
p. 151-152
2 p.
|
artikel
|
| 272 |
PSG6: COST-MINIMIZATION ANALYSIS OF EPOETIN ALPHA IN THE COMMUNITY HOSPITAL
|
Santorello, JG
|
|
2000
|
3 |
2 |
p. 148-
1 p.
|
artikel
|
| 273 |
PSG3: COSTS INCURRED DURING INPATIENT ADMISSION FOR COMMON SURGERIES: PRELIMINARY RESULTS
|
Strassels, S
|
|
2000
|
3 |
2 |
p. 147-
1 p.
|
artikel
|
| 274 |
PSG12: HOSPITAL COST SAVINGS FROM SEVERITY-ADJUSTED LENGTH OF STAY FOLLOWING SURGERY FOR INTRA-ABDOMINAL INFECTION AND TREATMENT WITH PIPERACILLIN/ TAZOBACTAM OR IMIPENEM/CILASTATIN
|
Bjerke, S
|
|
2000
|
3 |
2 |
p. 150-151
2 p.
|
artikel
|
| 275 |
PSG1: INPATIENT UTILIZATION OF MEDICAL SERVICES ASSOCIATED WITH PERIPHERAL ARTERIAL DISEASE-RELATED INPATIENT PROCEDURES IN THE DEPARTMENT OF DEFENSE
|
Zachry, WM
|
|
2000
|
3 |
2 |
p. 146-147
2 p.
|
artikel
|
| 276 |
PSG8: LONG-TERM OUTCOMES AND RESOURCE USE ASSOCIATED WITH MYOMECTOMY
|
Subramanian, S
|
|
2000
|
3 |
2 |
p. 149-
1 p.
|
artikel
|
| 277 |
PSG13: PROPHYLAXIS OF POSTOPERATIVE NAUSEA AND VOMITING: TESTING THE VALUE OF A DOLASETRON-BASED ALGORITHM
|
Darkow, T
|
|
2000
|
3 |
2 |
p. 151-
1 p.
|
artikel
|
| 278 |
PSG10: RESTENOSIS AND MEDICAL COSTS FOLLOWING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY (PTCA) WITH AND WITHOUT STENT
|
Sen, S
|
|
2000
|
3 |
2 |
p. 150-
1 p.
|
artikel
|
| 279 |
PSG2: TEN-YEAR COSTS ASSOCIATED WITH PERIPHERAL ARTERIAL DISEASE-RELATED INPATIENT PROCEDURES IN THE DEPARTMENT OF DEFENSE
|
Zachry, WM
|
|
2000
|
3 |
2 |
p. 147-
1 p.
|
artikel
|
| 280 |
PSG5: THE ECONOMIC IMPACT OF THE USE OF PERFLUORO-N-OCTANE DURING RETINAL DETACHMENT SURGERY
|
Venkataraman, KS
|
|
2000
|
3 |
2 |
p. 148-
1 p.
|
artikel
|
| 281 |
PSG4: TRAUMATIC COLON INJURIES: DIFFERENCE IN HOSPITAL COSTS BY TYPE OF SURGICAL REPAIR
|
O'Brien, J
|
|
2000
|
3 |
2 |
p. 147-148
2 p.
|
artikel
|
| 282 |
PSS9: CLINICAL AND ECONOMIC OUTCOMES OF CORONARY ANGIOPLASTY ALONE OR IN COMBINATION WITH STENTS IN ACADEMIC HEALTH CENTERS: A RETROSPECTIVE DATABASE ANALYSIS
|
Oinonen, MJ
|
|
2000
|
3 |
2 |
p. 149-150
2 p.
|
artikel
|
| 283 |
PWP2: A METHODOLOGY TO MEASURE PRODUCTIVITY OF HEALTH OUTCOMES GROUPS
|
Sesti, AM
|
|
2000
|
3 |
2 |
p. 115-
1 p.
|
artikel
|
| 284 |
PWP6: A PRELIMINARY STUDY OF PROVISION OF PHARMACEUTICAL CARE IN COMMUNITY PHARMACY IN SINGAPORE: COST ANALYSIS & PATIENT WILLINGNESS TO PAY
|
Li, SC
|
|
2000
|
3 |
2 |
p. 116-117
2 p.
|
artikel
|
| 285 |
PWP4: A WILLINGNESS-TO-PAY ASSESSMENT OF TWO TREATMENTS FOR OBESITY
|
Trakas, K
|
|
2000
|
3 |
2 |
p. 116-
1 p.
|
artikel
|
| 286 |
PWP1: COMPARATIVE BURDEN OF ILLNESS AT TWO LARGE US COMPANIES
|
Wogen, S
|
|
2000
|
3 |
2 |
p. 114-115
2 p.
|
artikel
|
| 287 |
PWP3: CONSUMER PREFERENCES FOR DENTAL ANESTHESIA: PUTTING YOUR MONEY WHERE YOUR MOUTH IS
|
Matthews, D
|
|
2000
|
3 |
2 |
p. 115-116
2 p.
|
artikel
|
| 288 |
PWP5: WORK PRODUCTIVITY EFFECTS OF DIABETES: IMPLICATIONS FOR RESEARCH AND POLICY
|
Lavigne, JE
|
|
2000
|
3 |
2 |
p. 116-
1 p.
|
artikel
|
| 289 |
Q3: HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN AFRICAN AMERICAN MEN WITH PROSTATE CANCER: DATA FROM CaPSURE
|
Lubeck, DP
|
|
2000
|
3 |
2 |
p. 54-
1 p.
|
artikel
|
| 290 |
Ql: CONSUMER AND STAFF VALIDATION OF A SELF-ADMINISTERED HEALTH-RELATED QUALITY OF LIFE INSTRUMENT FOR INDIVIDUALS WITH SCHIZOPHRENIA
|
Barr, JT
|
|
2000
|
3 |
2 |
p. 53-54
2 p.
|
artikel
|
| 291 |
Q4: MINIMUM MEANINGFUL DIFFERENCE SCORES FOR THE IRRITABLE BOWEL SYNDROME QUALITY OF LIFE QUESTIONNAIRE (IBSQOL)
|
Watson, ME
|
|
2000
|
3 |
2 |
p. 54-55
2 p.
|
artikel
|
| 292 |
Q2: PATIENT PREFERENCES FOR TREATMENT OUTCOMES IN DISABLING TREMOR
|
Leidy, NK
|
|
2000
|
3 |
2 |
p. 54-
1 p.
|
artikel
|
| 293 |
R4: AVAILABILITY OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ASSOCIATED WITH INCREASED SURVIVAL AND LOWER COSTS AT A VA MEDICAL CENTER
|
McCollum, M
|
|
2000
|
3 |
2 |
p. 51-52
2 p.
|
artikel
|
| 294 |
R3: DONEPEZIL USE AND IMPACT ON COST AMONG PATIENTS WITH ALZHEIMER'S DISEASE
|
West, WA
|
|
2000
|
3 |
2 |
p. 51-
1 p.
|
artikel
|
| 295 |
R1: QUANTIFYING THE IMPACT OF INTERACTIONS BETWEEN HMG-COA REDUCTASE INHIBITORS (STATINS) AND CYTOCHROME P-450 INTERACTING DRUGS ON HEALTHCARE UTILIZATION: A POPULATION-BASED STUDY
|
Iskedjian, M
|
|
2000
|
3 |
2 |
p. 50-51
2 p.
|
artikel
|
| 296 |
R2: RISK FACTORS FOR SHORT-TERM DIABETES COMPLICATIONS: AN ANALYSIS OF LINKED ADMINISTRATIVE CLAIMS AND CLINICAL LABORATORY DATA
|
Menzin, J
|
|
2000
|
3 |
2 |
p. 51-
1 p.
|
artikel
|
| 297 |
S1: IMPACT OF COMMUNITY-ACQUIRED PNEUMONIA TREATMENT GUIDELINES ON LENGTH OF STAY AND COST
|
Merchant, SV
|
|
2000
|
3 |
2 |
p. 63-
1 p.
|
artikel
|
| 298 |
S4: METHODS FOR COMPARING AREAS UNDER RECEIVER OPERATING CHARACTERISTIC CURVES: APPLICATION IN SCREENING ACCURACY FOR DEPRESSION
|
Shaw, JW
|
|
2000
|
3 |
2 |
p. 64-
1 p.
|
artikel
|
| 299 |
S3: STATISTICAL METHOD FOR MODELING DUAL SELECTION BIAS: WOODWORK EFFECT AND DRUG SELECTION BIAS AMONG MULTIPLE ALTERNATIVES
|
Shi, L
|
|
2000
|
3 |
2 |
p. 63-64
2 p.
|
artikel
|
| 300 |
S2: USE OF ESTROGEN REPLACEMENT THERAPY IN MARYLAND MEDICAID FEMALES
|
Huang, X
|
|
2000
|
3 |
2 |
p. 63-
1 p.
|
artikel
|
Tijdschrift beschrijving